Bask Health Alternatives for Telehealth Brands

What problem should a Bask Health alternative solve?

Bask’s public plans page includes clinical and pharmacy connections alongside storefront and patient tools. A useful alternatives search therefore starts with the operating change you want, not the assumption that Bask is only a website builder. Do you need different commercial terms, a different configuration, more managed administration or a different clinical arrangement?

Its current plan names also differ from those in its July 31, 2026 plan article. Resolve the current package before using it as the baseline. The TEHR versus Bask Health comparison explains the public-source inconsistency without treating it as proof of any particular contract terms.

Make a list of workflows that are working and workflows that need to change. Keep patient identity, clinical records, subscription billing, pharmacy relationships and support separate. An alternative may replace the full stack or preserve selected components; either approach needs a clear reason and an assigned operator.

Which operating models belong on the shortlist?

This shortlist groups different operating models. The order is editorial, with TEHR first, and does not represent independent testing or numerical scores. Vendor statements are presented as of October 22, 2026; a missing public detail means it needs confirmation, not that the capability is absent.

When is TEHR the right alternative to evaluate?

TEHR combines white-label technology and administrative infrastructure with an independent licensed clinical network reaching all 50 states, subject to program, state and patient eligibility. It supports clinician e-prescribing, pharmacy coordination, AI-assisted intake, payments and subscriptions. Clinical decisions remain with independent licensed providers. Its commercial model is a flat platform subscription plus flat transaction fee and 0% revenue share; contact TEHR for a scoped quote. See the platform and pricing scope.

TEHR is worth evaluating when you want an operator-led implementation and a stated flat subscription plus flat transaction model. Ask the team to demonstrate how the proposed operation handles recurring orders and exceptions, using your existing workflow as the starting point. The relevant question is whether the new division of administrative work is better suited to your team, not whether a different homepage looks more polished.

Trade-off: Confirm the actual clinical, pharmacy, support and integration scope before treating a platform proposal as an all-inclusive service. Patients see the brand, while required notices still identify the real care entities. Selected peptide programs are pending and are not open for prescribing or fulfillment.

When should you consider Telegra?

Strength: Telegra describes intake, commerce, pharmacy routing, a branded portal/app and APIs. Its public migration documentation covers CSV imports for patients, products, coupons, orders and subscriptions, with dry-run validation before production import. This is documented import capability, not proof of every outbound export option. Official platform overview; CSV migration.

Consider Telegra when an integrated commerce and patient experience is the principal requirement. Review the portal, plan-specific mobile app and operational dashboard in the context of your recurring service. Its import documentation is useful, but a complete transition also needs clinical history, billing reconciliation and patient communication.

Trade-off: Request recurring costs separately from published onboarding fees and confirm plan-specific app and pharmacy options. Its conditions page marks peptides Coming Soon; that is not a currently available prescribing or fulfillment program. Conditions and program status.

When should you consider OpenLoop?

Strength: OpenLoop’s Launchpad describes a no-code website, branded portal, intake, clinicians and operating workflows. The current product is broader than a clinician network; its official page also describes integration into existing customer systems. Official launchpad and platform.

Consider OpenLoop when you want to evaluate a turnkey operating platform with clinical, pharmacy and diagnostic infrastructure. Its current Launchpad scope is broader than staffing. Ask how much configuration your team retains and how ongoing changes to the brand or program are handled after the initial launch.

Trade-off: The reviewed page does not establish a universal numeric rate card or revenue-share policy. Request itemized terms and identify the work your team retains. Treat its fastest launch statement as a vendor estimate with readiness conditions, not a migration guarantee.

When should you consider Cuvo Health?

Strength: Cuvo’s pricing page publishes platform plans and a completed-consult charge, explicitly states no revenue share or added platform transaction fee, and describes patient/data migration without an additional migration charge. It also distinguishes full-platform plans from its existing-stack Prescribe option. Official pricing.

Consider Cuvo when an explicit published plan structure and migration offer help compare procurement options. Test the quote against your actual program mix and volume. Its no-revenue-share and no-added-platform-transaction-fee claims still leave setup, consult, payment and other service costs to evaluate.

Trade-off: Include setup, recurring and clinical charges in the comparison; standard payment-processing and other delivery costs still matter. A clinical connection to an existing stack has different dependencies from building a full brand. Confirm what its migration offer covers for your actual records.

When should you consider CareValidate?

Strength: CareValidate describes integrated white-label infrastructure and a nationwide provider network. Its laboratory page outlines both at-home kits and in-person orders, with results connected to charts and provider workflows. Its launch materials describe managed patient support and existing-stack API connectivity. Official provider network; Labs and diagnostics.

Consider CareValidate when the intended improvement is a more connected operating workflow, particularly for programs involving laboratory testing. Ask to see how results, patient support and fulfillment connect in practice. Public feature breadth should lead to a detailed scope discussion, not an assumption that every administrative task is included.

Trade-off: Request an itemized fee schedule and migration scope; neither was established on the reviewed public pages. Confirm which support tasks and lab costs are included. A broadly integrated offering still needs a clear handoff when a patient needs clinical rather than administrative help. Launch telehealth.

When should you consider FUSE Health?

Strength: FUSE describes white-label storefront, intake, portal, payments and operational infrastructure with different support levels. Its pricing page labels a percentage-based merchant service fee and contains inconsistent DIY monthly amounts between plan cards and FAQ text. Confirm the current written terms. Official how it works; Pricing.

Consider FUSE when the amount of launch work you want to outsource is a central decision. Compare the DIY, guided and managed approaches against your team’s capacity. Reconcile its current pricing inconsistency and calculate merchant service fees explicitly instead of comparing only the headline monthly platform amount.

Trade-off: Model the merchant service fee using the vendor’s terminology, separately from payment processing and clinical costs. Do not recast it as an independently verified revenue-share contract. Decide whether you want self-service configuration or managed implementation before comparing launch packages.

When should you consider Beluga Health?

Strength: Beluga offers direct API, hosted intake and platform-partner configurations. Its pricing page explicitly describes no cut of customer revenue, flat monthly access, per-visit fees and pharmacy/lab pass-through with disclosed service charges. Dollar amounts are quoted during scoping. Official platform integration paths; Pricing.

Consider Beluga when the storefront and commerce layer are worth retaining or replacing independently of clinical services. Its modular architecture can suit a brand with a capable technical and operating team. Identify the software and support around the clinical backend before treating its quoted visit economics as the cost of a full replacement.

Trade-off: Determine which company supplies commerce, subscriptions and patient support in your chosen configuration. A clinical backend can be the right fit for an existing stack, but its fee alone should not be compared with the price of a complete commercial operation.

When should you consider Lithos Health?

Strength: Lithos describes a white-label medical practice delivered through an API while customers build their own product. Its pricing page publishes per-completed-visit bands, and its migration page describes staged transitions with parallel testing and clinical continuity work. Official practice infrastructure; Pricing.

Consider Lithos when you want your own product team to control the experience and use a clinical practice API behind it. This changes the scope of the purchase rather than supplying a like-for-like storefront replacement. Account for engineering, support and commerce operations alongside the published visit rates.

Trade-off: The brand must account for building and operating the customer-facing product. Compare the appropriate modality and graduated volume bands, not only the lowest advertised visit rate. Public migration guidance is useful, but your source records and program still determine the plan. Migration.

How should you narrow the shortlist?

Choose a shortlist by operating style. If your team wants more control over configuration, ask to see the tools and permissions it will use. If it wants more managed administration, ask which recurring tasks the vendor actually performs. A vendor can have configurable software and still leave routine support work with the brand.

Compare a full renewal cycle, not only a first sale. Have each finalist show a patient who needs a clinical follow-up, a payment method change, a pharmacy exception and an administrative refund. Confirm who sees the relevant status and who can act. This reveals whether the proposed platform and support scope address the friction that prompted the search.

Use TEHR pricing to define one fee model, then request comparable current quotes. Include implementation, subscription, transaction, clinical, pharmacy, payment and retained staffing costs. Avoid invented revenue-share comparisons or treating a processing percentage as the same thing as a share of revenue.

How should existing patients move to the chosen platform?

A Bask transition should begin with authorized exports and a record of where information lives. Establish the source for profiles, charts, intake, consents, orders, subscriptions and payment credentials. Obtain representative data before committing to the new platform’s import design.

The Bask migration guide and patient migration checklist focus on validation and continuity. Agree on responsibility for the next refill and next charge for active customers. A new checkout can be ready while existing subscriptions and clinical follow-up remain unresolved, so test both new and continuing patient journeys.

What should the final proposal make explicit?

Ask for the service boundaries, itemized charges, implementation dependencies and operational acceptance criteria in writing. Review the white-label telehealth guide if the proposals use the same label for different scopes, and use the resource library to prepare program and migration questions. A good shortlist should become a small set of comparable proposals. It should not end as a ranking that hides unanswered questions about who supplies care, who performs administrative work and what the brand will actually pay.

For a wider category view, compare the white-label telehealth platform shortlist and the turnkey telehealth platform shortlist. Use the first to examine brand and architecture choices, and the second to assess which implementation and operating tasks a proposed package actually supplies.

What else should you know?